MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Decapeptide-12 Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Decapeptide-12 (Lumixyl) is a synthetic skin-brightening peptide, sequence YRSRKYSSWY (~1,395 Da), that competitively inhibits tyrosinase, the rate-limiting enzyme of melanin synthesis. In vitro it is roughly 17-fold more potent than hydroquinone and, unlike hydroquinone, reduces melanin without melanocyte cytotoxicity (PMID 19440221). Clinically it is used as a 0.01% (100 ppm) topical cream applied twice daily, usually with a buffered glycolic-acid lotion and sunscreen; open-label studies show progressive lightening of melasma, post-inflammatory hyperpigmentation, and photodamage, with mean MASI reductions near 60% at 16 weeks and no reported adverse events (PMID 23839199, PMID 22401652). The native peptide penetrates skin poorly because it is hydrophilic and large, so palmitoylation, chemical enhancers, microneedles, and dermalinfusion have been studied to improve delivery (PMID 34242628). It is a cosmetic ingredient, not an FDA- or EMA-approved drug; the subcutaneous reconstitution figures here are an educational measurement reference only.
Reconstitute: Add 2 mL bacteriostatic water → 2.5 mg/mL concentration.
Typical dose: 0.01% topical (~100 mcg per application), 2x/day
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 0.0250 mg (25 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen at −20 °C, protected from light and moisture. Once blended into a topical base or reconstituted in bacteriostatic water, refrigerate at 2-8 °C and use within roughly 4 weeks. Finished commercial 0.01% creams are typically stored at room temperature per their label.
Half-life: No established systemic half-life; acts locally in the epidermis. The native peptide is hydrophilic and ~1,395 Da, so transdermal penetration is limited and systemic exposure is negligible (PMID 34242628).
Route: Topical cosmetic: 0.01% (100 ppm) cream applied twice daily. The subcutaneous reconstitution scheme on this page is an educational measurement reference only, not a real-world route.
Status: Cosmetic ingredient (INCI: Decapeptide-12); not FDA- or EMA-approved as a drug. Educational content only, not medical advice.
About Decapeptide-12
Decapeptide-12 (trade name Lumixyl) is a synthetic 10-amino-acid peptide (Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr) developed as a competitive tyrosinase inhibitor for skin brightening [1][2]. In every published clinical study it is used TOPICALLY at 0.01% (100 ppm) in a cream, applied twice daily to areas of melasma, post-inflammatory hyperpigmentation, or photodamage [3][5]. It is a cosmetic ingredient, not an injectable drug; the subcutaneous reconstitution figures below are an educational measurement reference only, mirroring how this site models topical and oral compounds.\n\nFor that educational model, a 5 mg vial is reconstituted with 2.0 mL of bacteriostatic water (2.5 mg/mL, i.e. 25 mcg per insulin-syringe unit) so that topical-equivalent amounts map cleanly onto a U-100 syringe: roughly 100 mcg (≈4 units) per application is comparable to the amount of peptide delivered by about 1 g of a 0.01% cream. A typical Decapeptide-12 dosage schedule starts with a single daily patch-test application, then moves to the studied twice-daily routine [3][5].\n\nFrequency: Twice daily (morning and evening), used alongside sunscreen and often a buffered glycolic-acid lotion. Decapeptide-12 is a cosmetic ingredient and is not an FDA- or EMA-approved drug; this page is educational, not medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 5 mg Decapeptide-12 vial; do not aim the stream directly at the powder, and avoid vigorous shaking.
Swirl or roll the vial gently until the solution is completely clear; the result is a 2.5 mg/mL concentration (25 mcg per U-100 insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed amount per use (50 mcg ≈ 2 units; 100 mcg ≈ 4 units).
Educational note: Decapeptide-12 is a TOPICAL cosmetic peptide applied twice daily — these subcutaneous figures are a measurement reference only; in real-world use the powder is blended into a 0.01% cream and smoothed onto clean skin, not injected.
Interactive Decapeptide-12 Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 2mL water yields 2.50 mg/mL. To evaluate a 250mcg dose, pull to 10.0 units (10 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Patch test / introduction (week 1, once daily) | 50 mcg | 2 units (0.02 mL) |
| Standard brightening (weeks 2-16, twice daily) | 100 mcg | 4 units (0.04 mL) |
| Maintenance (twice daily) | 100 mcg | 4 units (0.04 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (Decapeptide-12, 5 mg each):
- check8 weeks at ~100 mcg twice daily ≈ 3 vials (~11 mg total)
- check12 weeks at ~100 mcg twice daily ≈ 4 vials (~17 mg total)
- check16 weeks at ~100 mcg twice daily ≈ 5 vials (~22 mg total)
- checkIn real-world cosmetic use the powder is blended into a 0.01% cream rather than drawn from vials
Insulin Syringes (U-100):
- checkTwice-daily dosing in the educational model: 14 syringes per week
- check8 weeks ≈ 112 syringes; 12 weeks ≈ 168 syringes; 16 weeks ≈ 224 syringes
- checkDoses are small (50 mcg ≈ 2 units, 100 mcg ≈ 4 units), so one syringe easily covers a single application
- checkNote: real-world topical use needs no syringes; the peptide is smoothed onto skin
Bacteriostatic Water (30 mL bottles): Use 2 mL per 5 mg vial for reconstitution.
- check8 weeks ≈ 3 vials ≈ 6 mL
- check12 weeks ≈ 4 vials ≈ 8 mL
- check16 weeks ≈ 5 vials ≈ 10 mL
- checkA single 30 mL bottle comfortably covers a full 16-week educational course
Alcohol Swabs:
- check1-2 swabs per use (vial top plus skin/site)
- check8 weeks ≈ 110-225 swabs; 12 weeks ≈ 170-340 swabs
- check16 weeks ≈ 225-450 swabs; keep extras for re-swabbing the multi-use vial
- checkFor topical use, swab the vial top and clean the skin before each application
Mechanism of Action (MOA)
Decapeptide-12 is a synthetic 10-residue oligopeptide with the sequence Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr (YRSRKYSSWY), a molecular weight of approximately 1,395 Da, and the molecular formula C65H90N18O17. It is marketed under the trade name Lumixyl and emerged from a peptide-library screen for tyrosinase inhibitors reported by Abu Ubeid, Hantash and colleagues, in which sequences enriched in tyrosine, arginine and serine showed strong anti-tyrosinase activity [1][2].\n\nTyrosinase is the rate-limiting, copper-containing enzyme of melanogenesis: it hydroxylates L-tyrosine to L-DOPA and oxidizes L-DOPA to dopaquinone, the committed steps that ultimately generate melanin pigment. Decapeptide-12 acts as a competitive inhibitor of tyrosinase; its tyrosine residues are thought to compete with the natural substrate at or near the enzyme's active site. In vitro it inhibited mushroom tyrosinase with an IC50 of roughly 40 µM, compared with about 680 µM for hydroquinone — an approximately 17-fold potency advantage — and it inhibited human tyrosinase by about 25-35% at 100 µM [1]. Critically, it lowers melanin output by reducing enzyme activity rather than by killing pigment cells: in cultured human melanocytes, seven-day exposure reduced melanin content by 27-43% without cytotoxicity, a key distinction from hydroquinone, which can be toxic to melanocytes [1].\n\nDownstream, by throttling new melanin synthesis while normal epidermal turnover gradually sheds keratinocytes that already carry pigment, dark spots fade slowly over weeks. Visible brightening typically appears after about 8 weeks and continues through 16-24 weeks of consistent twice-daily use [4][5].\n\nPharmacokinetics and delivery: Decapeptide-12 works locally in the epidermis. There is no meaningful systemic absorption or established plasma half-life; it is not designed to enter the circulation. The native peptide is hydrophilic and, at ~1,395 Da, sits well above the ~500 Da rule-of-thumb for efficient passive penetration of the stratum corneum, so skin uptake of the unmodified molecule is limited. Research has improved skin retention and permeation through structural modification (palmitoylation to add a lipophilic tail), chemical enhancers such as oleic acid and menthol, and microneedle-assisted delivery; in-office dermalinfusion has likewise been used to drive the peptide into pigmented skin [6][7]. Commercial formulations commonly pair the 0.01% peptide with 20% buffered glycolic acid, which exfoliates and aids penetration [3][5].\n\nReal-world route honesty: Decapeptide-12 is a topical cosmetic ingredient, not an injectable therapeutic. The subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a clinically validated delivery method, and the compound is not approved by any major drug regulator.
Clinical Trial Efficacy Highlights
- starAbu Ubeid, Zhao, Wang and Hantash (2009, J Invest Dermatol) screened short oligopeptides and identified decapeptide-12 as a competitive tyrosinase inhibitor with an IC50 of about 40 µM against mushroom tyrosinase versus roughly 680 µM for hydroquinone (about 17-fold more potent); it inhibited human tyrosinase by 25-35% at 100 µM and reduced melanocyte melanin content by 27-43% over seven days without cytotoxicity [1].
- starReddy, Jow and Hantash (2012, Experimental Dermatology) reviewed bioactive oligopeptides in dermatology and positioned decapeptide-12 (Lumixyl) as a well-tolerated, non-cytotoxic tyrosinase-inhibiting brightening agent, contrasting its low irritation profile with the cytotoxicity and rebound risks associated with hydroquinone [2].
- starHantash and Jimenez (2012, J Drugs Dermatol) reported a four-patient case series using a Lumixyl system containing 0.01% decapeptide-12 cream applied twice daily together with a 20% glycolic-acid lotion and SPF 30 sunscreen; all patients improved and one of four achieved complete clearance of facial melasma after just six weeks [3].
- starKassim, Hussain and Goldberg (2012, J Cosmet Laser Ther) ran a 24-week open-label trial in 15 women (Fitzpatrick I-IV) with photodamage using a decapeptide-12 brightening system; 38.5% of completers improved from moderate (grade 3) to fully cleared (grade 1) and a further 30.7% improved from moderate to mild, with no adverse effects [4].
- starRamirez and colleagues (2013, J Drugs Dermatol) evaluated 0.01% decapeptide-12 plus 20% buffered glycolic acid in 33 Hispanic women with mild-to-moderate facial melasma and recorded mean MASI reductions of 36%, 46%, 54% and 60% at weeks 4, 8, 12 and 16 respectively, with no adverse events reported [5].
- starBhatia, Hsu and Hantash (2014, J Drugs Dermatol) combined topical decapeptide-12 with dermalinfusion in skin of color and observed accelerated resolution of post-inflammatory hyperpigmentation compared with topical delivery alone, illustrating that enhanced delivery improves outcomes for this hydrophilic peptide [6].
- starChen and colleagues (2021, Int J Pharm) addressed the delivery limitation directly, showing that the native peptide penetrates skin poorly because of its hydrophilicity and high molecular weight, while palmitoylation achieved the best skin retention and microneedles enhanced penetration of the unmodified peptide; they noted reported topical efficacy exceeding 50% improvement after 16 weeks of twice-daily treatment [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningIn open-label clinical studies the 0.01% decapeptide-12 cream was non-irritating and well tolerated, with no peptide-attributable adverse events reported across photodamage and melasma trials [3][4][5].
- warningMost stinging, transient erythema, dryness or peeling seen with Lumixyl regimens is attributable to the accompanying 20% buffered glycolic-acid lotion rather than to the peptide itself; reducing glycolic-acid frequency usually resolves it [3][5].
- warningAs with any topical peptide, allergic contact dermatitis or sensitization is theoretically possible; a patch test before full-face use is prudent, especially in sensitive or reactive skin.
- warningDecapeptide-12 is not a sunscreen and does not prevent new pigment formation from UV exposure; daily broad-spectrum photoprotection is required or melasma and post-inflammatory hyperpigmentation will recur or worsen [5].
- warningBecause the native peptide is hydrophilic and large (~1,395 Da), passive skin penetration is limited; results can be slow or modest without delivery enhancement (exfoliation, palmitoylation, microneedles, or in-office dermalinfusion) [6][7].
- warningSubcutaneous injection is NOT a validated or intended route for this cosmetic ingredient; the SC figures here are an educational measurement reference only, and injecting research-grade powder carries real risks of infection, contamination, unknown purity, and immune reaction.
- warningSafety data are limited to short-term topical use (up to ~24 weeks) in small studies; long-term and systemic safety have not been established.
- warningRegulatory/research status: Decapeptide-12 is regulated as a cosmetic ingredient (INCI: Decapeptide-12), not as an FDA- or EMA-approved drug; this content is educational only and not medical advice.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Decapeptide-12 dosage?expand_more
In every published study the Decapeptide-12 dosage is a 0.01% (100 ppm) topical cream applied twice daily, morning and evening, to areas of melasma, post-inflammatory hyperpigmentation, or photodamage (Hantash 2012, Ramirez 2013). It is usually layered into a routine with a buffered glycolic-acid lotion and broad-spectrum sunscreen. Because it is a cosmetic ingredient measured in micrograms per application rather than an injectable drug, the subcutaneous reconstitution figures on this page (for example ~100 mcg ≈ 4 units of a 2.5 mg/mL solution) are only an educational measurement reference, not a real-world route.
Is Decapeptide-12 FDA approved?expand_more
No. Decapeptide-12 is regulated as a cosmetic ingredient (INCI name: Decapeptide-12), not as an approved drug. It has not been approved by the FDA or EMA for any therapeutic indication, and it has not gone through new-drug approval; its evidence base is small open-label cosmetic studies. As a cosmetic it can be sold in topical products, but no agency has cleared it to diagnose, treat, or cure a medical condition. This page is educational only and not medical advice.
What is the half-life of Decapeptide-12?expand_more
Decapeptide-12 has no established systemic plasma half-life because it is a topical cosmetic peptide that acts locally in the epidermis rather than entering the bloodstream. The native molecule is hydrophilic and relatively large (~1,395 Da), which limits passive penetration through the stratum corneum, so it is meant to remain in the skin where it inhibits tyrosinase. Its practical 'duration of action' is governed by twice-daily reapplication and by how much peptide is retained in the skin, which is why delivery enhancers, palmitoylation, and microneedles have been studied (Chen 2021).
How is Decapeptide-12 reconstituted and applied?expand_more
In real-world use there is no injection: the peptide powder is blended into a 0.01% topical cream and smoothed onto clean skin twice daily. For the educational subcutaneous model on this site, a 5 mg vial is mixed with 2.0 mL of bacteriostatic water to give 2.5 mg/mL (25 mcg per U-100 unit); draw the water slowly down the vial wall, swirl gently until clear, and refrigerate. At that concentration 50 mcg is about 2 units and 100 mcg is about 4 units, mirroring the amount of peptide delivered by roughly 1 g of a 0.01% cream.
Can Decapeptide-12 be stacked with other ingredients?expand_more
Yes. In cosmetic practice decapeptide-12 is frequently combined with a buffered glycolic-acid exfoliant (to improve penetration and turnover), broad-spectrum sunscreen (essential to prevent new pigment), and other brighteners such as vitamin C, niacinamide, kojic acid, or azelaic acid. The clinical studies themselves used it within a multi-step system. Because the peptide is non-cytotoxic and non-irritating, it generally layers well, but stacking several actives can increase irritation, so introduce one product at a time and patch-test first.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Decapeptide-12, plus the universal dosing calculator.
Academic References & Study Citations
Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009;129(9):2242-2249. View Scientific Paper →
Reddy BY, Jow T, Hantash BM. Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. 2012;21(8):563-568. View Scientific Paper →
Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. View Scientific Paper →
Kassim AT, Hussain M, Goldberg DJ. Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12. J Cosmet Laser Ther. 2012;14(2):117-121. View Scientific Paper →
Ramirez SP, Carvajal AC, Salazar JC, et al. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermatol. 2013;12(6):e106-e110. View Scientific Paper →
Bhatia A, Hsu JT, Hantash BM. Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color. J Drugs Dermatol. 2014;13(1):84-85. View Scientific Paper →
Chen J, Bian J, Hantash BM, et al. Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles. Int J Pharm. 2021;606:120868. View Scientific Paper →